HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Limited (NYSE:RDY) announced today, that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application ("ANDA") for Ondansetron Hydrochloride Tablets, 4 mg, 8mg, 16 mg and 24 mg. As the first company to file an ANDA containing a paragraph IV certification for this product, Dr. Reddy’s has been awarded a 180-day period of marketing exclusivity. The Company will commence the shipment of this product shortly.
